Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pebblestone: Baloxavir Marboxil in Pediatric Patients With Influenza
NCT06094010Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of baloxavir marboxil in influenza, sponsored by Roche. Primary endpoints: Percentage of Participants With Resistance-associated Pre-treatment Substitutions at Day 1 and Percentage of Participants With Resistance-associated Treatment-emergent Substitutions at Day 10. Started Nov 2023; status: recruiting.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06094010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094010.